| scholarly article | Q13442814 |
| P2093 | author name string | Xu Liu | |
| Hsiang-Fu Kung | |||
| Xiaomei Wang | |||
| Fang Yang | |||
| Ying Zhu | |||
| Hongjian Li | |||
| Kwong-Sak Leung | |||
| Man-Hon Wong | |||
| Chao Dong | |||
| Ceshi Chen | |||
| Guimiao Lin | |||
| Marie Chia-Mi Lin | |||
| Xi-Nan Shi | |||
| Runxiang Yang | |||
| Kunbin Ke | |||
| Chunxiang Luo | |||
| P2860 | cites work | Comparative Studies of Steroidogenesis Inhibitors (Econazole, Ketoconazole) on Human Breast Cancer MCF-7 Cell Proliferation by Growth Experiments, Thymidine Incorporation and Flow Cytometric DNA Analysis | Q67838159 |
| DrugBank 4.0: shedding new light on drug metabolism | Q24568341 | ||
| PI3K inhibitors as new cancer therapeutics: implications for clinical trial design | Q26770489 | ||
| Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor | Q27676347 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials | Q27852946 | ||
| Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. | Q27853128 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Oncogenic mutations of PIK3CA in human cancers | Q28284802 | ||
| istar: a web platform for large-scale protein-ligand docking | Q28306830 | ||
| In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug | Q28546330 | ||
| Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy | Q29248893 | ||
| AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility | Q29547658 | ||
| ZINC: a free tool to discover chemistry for biology | Q29615857 | ||
| The emerging mechanisms of isoform-specific PI3K signalling | Q29617954 | ||
| Analysis of dissolution data using modified versions of Noyes-Whitney equation and the Weibull function. | Q31030017 | ||
| Improving AutoDock Vina Using Random Forest: The Growing Accuracy of Binding Affinity Prediction by the Effective Exploitation of Larger Data Sets | Q31119539 | ||
| Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma | Q33439741 | ||
| Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways | Q33709769 | ||
| PIK3CA mutations and copy number gains in human lung cancers | Q33870342 | ||
| Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking | Q34373100 | ||
| Econazole Nitrate Induces Apoptosis in MCF-7 Cells via Mitochondrial and Caspase Pathways | Q34515961 | ||
| The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics | Q34992596 | ||
| PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup | Q35095308 | ||
| iview: an interactive WebGL visualizer for protein-ligand complex. | Q35101614 | ||
| PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies | Q35176080 | ||
| Odorant Stimulation Promotes Survival of Rodent Olfactory Receptor Neurons via PI3K/Akt Activation and Bcl-2 Expression | Q35749726 | ||
| Inexpensive Method for Selecting Receptor Structures for Virtual Screening. | Q35864805 | ||
| Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study | Q36284430 | ||
| The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia | Q36379644 | ||
| Mutation of the PIK3CA oncogene in human cancers | Q36383360 | ||
| Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells | Q36485168 | ||
| New targetable oncogenes in non-small-cell lung cancer | Q36660677 | ||
| Therapeutic applications of PARP inhibitors: anticancer therapy and beyond | Q36853236 | ||
| The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer | Q37183710 | ||
| Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology | Q37359022 | ||
| The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer | Q37464641 | ||
| Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors | Q38205751 | ||
| Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells | Q38717250 | ||
| Effect of the pesticide, deltamethrin, on Ca2+ signaling and apoptosis in OC2 human oral cancer cells | Q39129874 | ||
| Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors | Q39266844 | ||
| Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer | Q39768554 | ||
| A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells | Q39840228 | ||
| Ocimum sanctum induces apoptosis in A549 lung cancer cells and suppresses the in vivo growth of Lewis lung carcinoma cells | Q39874385 | ||
| Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor. | Q39884490 | ||
| A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model | Q40211640 | ||
| Effects of econazole on Ca2+ levels in and the growth of human prostate cancer PC3 cells | Q40371030 | ||
| Molecular mechanisms of econazole-induced toxicity on human colon cancer cells: G0/G1 cell cycle arrest and caspase 8-independent apoptotic signaling pathways | Q40416707 | ||
| Clotrimazole potentiates the inhibitory effects of ATP on the key glycolytic enzyme 6-phosphofructo-1-kinase | Q43116947 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 17987 | |
| P577 | publication date | 2017-12-21 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells | |
| P478 | volume | 7 |
| Q64901523 | An in vivo Like Micro-Carcinoma Model. |
| Q90630076 | Econazole Induces p53-Dependent Apoptosis and Decreases Metastasis Ability in Gastric Cancer Cells |
| Q89737220 | Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway |
| Q91683149 | IL-25 promotes cisplatin resistance of lung cancer cells by activating NF-κB signaling pathway to increase of major vault protein |
Search more.